[go: up one dir, main page]

BRPI0808897B8 - uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278 - Google Patents

uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278

Info

Publication number
BRPI0808897B8
BRPI0808897B8 BRPI0808897A BRPI0808897A BRPI0808897B8 BR PI0808897 B8 BRPI0808897 B8 BR PI0808897B8 BR PI0808897 A BRPI0808897 A BR PI0808897A BR PI0808897 A BRPI0808897 A BR PI0808897A BR PI0808897 B8 BRPI0808897 B8 BR PI0808897B8
Authority
BR
Brazil
Prior art keywords
tmc278
dispersed
vinylpyrrolidone
copolymer
powder
Prior art date
Application number
BRPI0808897A
Other languages
English (en)
Inventor
Van Gyseghem Elke
René Jaak Van Den Mooter Guy
Elvire Colette Baert Lieven
Jozef Maria Van Remoortere Peter
Original Assignee
Janssen R & D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38055251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0808897(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R & D Ireland
Publication of BRPI0808897A2 publication Critical patent/BRPI0808897A2/pt
Publication of BRPI0808897B1 publication Critical patent/BRPI0808897B1/pt
Publication of BRPI0808897B8 publication Critical patent/BRPI0808897B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

pós para reconstituição. a presente invenção refere-se a pós para reconstituição compreendendo o nnrti tmc278 disperso em certos polímeros solúveis em água, que podem ser aplicados no tratamento de infecção por hiv.
BRPI0808897A 2007-03-14 2008-03-14 uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278 BRPI0808897B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104082 2007-03-14
EP07104082.8 2007-03-14
PCT/EP2008/053056 WO2008110619A1 (en) 2007-03-14 2008-03-14 Powders for reconstitution

Publications (3)

Publication Number Publication Date
BRPI0808897A2 BRPI0808897A2 (pt) 2014-09-02
BRPI0808897B1 BRPI0808897B1 (pt) 2020-10-20
BRPI0808897B8 true BRPI0808897B8 (pt) 2021-05-25

Family

ID=38055251

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808897A BRPI0808897B8 (pt) 2007-03-14 2008-03-14 uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278

Country Status (18)

Country Link
US (1) US8916558B2 (pt)
EP (1) EP2043608B1 (pt)
JP (1) JP5554571B2 (pt)
KR (1) KR101580297B1 (pt)
CN (1) CN101636149B (pt)
AP (1) AP2964A (pt)
AR (2) AR065720A1 (pt)
AU (1) AU2008225774B2 (pt)
BR (1) BRPI0808897B8 (pt)
CA (1) CA2676981C (pt)
CL (1) CL2008000746A1 (pt)
ES (1) ES2535162T3 (pt)
IL (1) IL199874A (pt)
MX (1) MX2009009743A (pt)
RU (1) RU2477133C2 (pt)
TW (1) TWI494133B (pt)
WO (1) WO2008110619A1 (pt)
ZA (1) ZA200906344B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
JP6301339B2 (ja) * 2012-09-27 2018-03-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
BR112021026916A2 (pt) * 2019-07-03 2022-05-10 Janssen Sciences Ireland Unlimited Co Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
CN119403545A (zh) * 2022-04-22 2025-02-07 爱尔兰詹森科学公司 冷冻干燥的组合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US5182111A (en) 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
ES2093106T3 (es) * 1990-07-19 1996-12-16 Otsuka Pharma Co Ltd Preparacion solida.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH07503943A (ja) 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
WO1993023021A2 (en) 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP1214059B1 (en) 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
KR100785360B1 (ko) 1999-09-24 2007-12-18 얀센 파마슈티카 엔.브이. 항바이러스 조성물
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
MXPA02009534A (es) 2000-03-30 2003-05-14 Squibb Bristol Myers Co Granulos de liberacion sostenida que contienen estavudina.
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
WO2002048141A1 (fr) 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Composition medicinale dont la solubilite dans l'eau est amelioree
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
CA2686429C (en) 2002-08-09 2010-11-16 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7497855B2 (en) 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
AU2003291457A1 (en) 2002-11-08 2004-06-03 Glaxo Group Limited Pharmaceutical antiviral compositions
NZ540321A (en) 2002-11-15 2007-09-28 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
NZ541902A (en) 2003-02-07 2008-12-24 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
JP2008501802A (ja) * 2004-06-08 2008-01-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド 医薬組成物
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DK1632232T6 (da) 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
KR20130030305A (ko) 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
AU2006235565A1 (en) 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
TW200710091A (en) * 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
EP1912730A2 (en) 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
JP5754005B2 (ja) 2006-01-20 2015-07-22 ヤンセン・アールアンドデイ・アイルランド Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
AU2007255418C1 (en) 2006-06-06 2011-08-18 Janssen Sciences Ireland Uc Process for preparing spray dried formulations of TMC125
AR061620A1 (es) 2006-06-23 2008-09-10 Tibotec Pharm Ltd Suspensiones acuosas de tmc278
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
HRP20131128T1 (hr) 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
US20110257111A1 (en) 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives

Also Published As

Publication number Publication date
JP5554571B2 (ja) 2014-07-23
ZA200906344B (en) 2015-04-29
IL199874A (en) 2016-02-29
US20100120795A1 (en) 2010-05-13
RU2477133C2 (ru) 2013-03-10
JP2010520918A (ja) 2010-06-17
CN101636149A (zh) 2010-01-27
IL199874A0 (en) 2010-04-15
EP2043608B1 (en) 2015-01-21
BRPI0808897B1 (pt) 2020-10-20
WO2008110619A1 (en) 2008-09-18
CA2676981A1 (en) 2008-09-18
AU2008225774A1 (en) 2008-09-18
TW200911303A (en) 2009-03-16
AR114086A2 (es) 2020-07-22
KR101580297B1 (ko) 2015-12-24
AR065720A1 (es) 2009-06-24
EP2043608A1 (en) 2009-04-08
CL2008000746A1 (es) 2008-09-22
TWI494133B (zh) 2015-08-01
RU2009137911A (ru) 2011-04-20
AP2009004969A0 (en) 2009-10-31
MX2009009743A (es) 2009-09-23
ES2535162T3 (es) 2015-05-05
AP2964A (en) 2014-09-30
KR20090119964A (ko) 2009-11-23
CA2676981C (en) 2015-01-13
AU2008225774B2 (en) 2014-04-10
CN101636149B (zh) 2014-08-06
US8916558B2 (en) 2014-12-23
BRPI0808897A2 (pt) 2014-09-02

Similar Documents

Publication Publication Date Title
BRPI0808897B8 (pt) uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278
HK1203489A1 (en) Purinone compounds as kinase inhibitors
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
HK1206362A1 (zh) 硫代氨基磷酸酯核苷酸前藥的固體形式
IL246181A0 (en) Methods of producing retinal pigment epithelium (rpe) cells, compositions comprising the same, and uses thereof in the preparation of medicaments for treating or preventing a condition characterized by retinal degeneration
MX2015014890A (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados.
HK1223949A1 (zh) 稳定的可溶性预融合rsv f多肽
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
CL2008000751A1 (es) Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c.
BR112018011501A2 (pt) copolímeros em bloco de formação de camada de polieletrólito e composições e usos dos mesmos
EA201270264A1 (ru) Лечение метастазов в головной мозг ингибиторами рецепторов эндотелина в комбинации с цитотоксическим химиотерапевтическим средством
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
BR112015014760A2 (pt) complexo de zinco-aminoácido com cisteína
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
WO2010110685A8 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
TW200621268A (en) Antimicrobial copolymers and uses thereof
WO2010085100A2 (ko) 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
BR112013027356A2 (pt) composição compreendendo aflibercept, ácido folínico, 5-fluorouacila (5-fu) e irinocetano (folfiri)
TR200806298A2 (tr) Farmasötik formülasyon
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
IN2014DE01722A (pt)
EP4226937A3 (en) Non-neuroinvasive viruses and uses thereof
WO2010006697A3 (en) Powders for reconstitution

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.